The COVID Boom: CBER Receives More INDs in One Quarter Than The Previous 30 Combined

 
• By Derrick Gingery
  
Hand grabbing rising line
CBER continued to see INDs for cell and gene therapies, in addition to COVID-19 countermeasures, in recent months. • Source: Alamy
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from United States

More from North America